#	Pagina
attuale pagina	/open-h2020/projects/196475/index.html
-1	/open-h2020/projects/201148/index.html
-2	/open-h2020/projects/201302/index.html
-3	/open-h2020/per-topic/extinction/list/index.html
-4	/open-fp7/projects/94748/index.html

Opendata, web and dolomites

Vaprosep

Validation of Progranulin as Biomarker in Diagnostics and Prognosis of Sepsis

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

Vaprosep project word cloud

Explore the words cloud of the Vaprosep project. It provides you a very rough idea of what is the project "Vaprosep" about.

time completion unnecessary therapy employees subsequent inducing intellectual disease agent care advantages biomarker 500 inflammatory qualified preliminary interviewed administrative questionnaire regarding economic validation bodies 094 scientific regulatory data property worldwide patient health sensitive mediagnost direct technically hospital hospitals picture successful differentiation delay structured leaders reimbursement infrastructure prognosis reaction million avoidance literature stay excellent incidence host prove guarantee day systemic feasibility opinion multiplex icu routine successfully 1000 sepsis market contact length reduce validated complete therapeutic detection rate solidity point clinical strategy strategic infectious 12 monitoring mean progranulin antibiotic notified course infection

Project "Vaprosep" data sheet

The following table provides information about the project.

Coordinator	MEDIAGNOST GESELLSCHAFT FUR FORSCHUNG UND HERSTELLUNG VON DIAGNOSTIKA GMBH Organization address address: ASPENHAUSTRASSE 25 city: REUTLINGEN postcode: 72770 website: www.mediagnost.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Germany [DE]
Project website	http://www.mediagnost.de/en/news/summary-of-sme-instrument-phase-i-project-vaprosep-2/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2014
Funding Scheme	SME-1
Starting year	2015
Duration (year-month-day)	from 2015-05-01 to 2015-09-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	MEDIAGNOST GESELLSCHAFT FUR FORSCHUNG UND HERSTELLUNG VON DIAGNOSTIKA GMBH MEDIAGNOST GESELLSCHAFT FUR FORSCHUNG UND HERSTELLUNG VON DIAGNOSTIKA GMBH Organization address address: ASPENHAUSTRASSE 25 city: REUTLINGEN postcode: 72770 website: www.mediagnost.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (REUTLINGEN)	coordinator	50˙000.00

Map

Project objective

Sepsis is a complex, systemic and inflammatory host reaction on an infection and with worldwide 1.5 million cases per year a health challenge. There is a strong need for a reliable biomarker like progranulin. Preliminary data prove that progranulin allows a highly sensitive and specific detection of sepsis, a monitoring of infection without time delay, prognosis regarding disease course and a differentiation between the infectious agent inducing sepsis.

Economic advantages of progranulin as biomarker are the reduction of the length of stay in the ICU (500-1000€ / day) and avoidance of unnecessary antibiotic therapy (10-500€ / day). Thus, the hospital can improve patient care and reduce therapeutic costs by a progranulin measurement for 5-10€. A mean incidence rate of 0.094% results in a 12 million euro market in the US and EU. Based on intellectual property this market is available only for Mediagnost. Successfully validated, progranulin measurement will be introduced in third level hospitals in the EU. The subsequent strategic product development includes point of care and multiplex test systems.

Mediagnost already has a technically validated test system for this biomarker available, therefore the overall objectives of this study are the clinical validation of progranulin measurement in sepsis and its implementation in clinical routine. Specifically, in phase I the economic potential of this biomarker is evaluated.

These objectives are addressed during phase I in a feasibility study including market and cost analysis. Key opinion leaders in the EU are interviewed by a structured questionnaire to evaluate scientific solidity and market potential. In direct contact to EU Notified Bodies the best regulatory strategy is evaluated. Further, literature research will complete the picture of the market and reimbursement requirements. Excellent infrastructure and highly qualified scientific and administrative employees guarantee the successful completion of this work.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VAPROSEP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VAPROSEP" are provided by the European Opendata Portal: CORDIS opendata.